Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...151152153154155156157158159160161...401402»
  • ||||||||||  losartan / Generic mfg.
    Preclinical, Journal:  Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat Aging Model. (Pubmed Central) -  Nov 5, 2022   
    BMI at the onset had a negative association with sarcopenia among SSc patients. Losartan treatment slowed muscle degeneration and activated the PI3K-AKT-mTOR and ERK/mitogen-activated protein kinase signalling pathways required for production of muscle growth factors when combined with exercise.
  • ||||||||||  Review, Journal:  Androgenic Steroids Use and Abuse: Past, Present, and Future. (Pubmed Central) -  Nov 5, 2022   
    There is a risk of a withdrawal syndrome that includes severe depression, and there seems to be an increased risk of cardiovascular disease associated with chronic abuse. In contrast to high-dosage androgen abuse, androgen therapy at near-physiological dosages is generally safe and effective for male hypogonadism and potential use in sarcopenia and male hormonal contraception.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
    Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_6500;    
    The link between visceral adipose tissue and improved survival suggests that the obesity paradox may extend to patients receiving T-cell based immunotherapies. If validated in future prospective studies, data on body composition and nutritional status may complement existing risk-stratification tools for patients receiving CD19-CART, and may lead to exercise- and diet-based interventional strategies.
  • ||||||||||  Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4554;    
    Patients in the upper or lower tertiles for SAT area had decreased OS compared to those in the middle tertile. High SAT radiodensity and low muscle radiodensity were associated with advanced disease stage and adverse laboratory characteristics.
  • ||||||||||  carboplatin / Generic mfg., cisplatin / Generic mfg., cyclophosphamide / Generic mfg.
    Frailty and Sarcopenia within the Earliest Dutch Childhood Cancer Survivor Cohort (n=2,003): A Dccss-Later Study (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4112;    
    Our findings show that frailty and sarcopenia occur already at a mean age of 33 years in childhood cancer survivors, i.e., conceivably more than three decades earlier than in the general population. Early recognition and interventions for endocrine disorders and dietary deficiencies may be crucial in minimizing the risk of (pre)frailty and sarcopenia in this population.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Carvykti (ciltacabtagene autoleucel) / J&J
    Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_2913;    
    MM Treatment combinations frequently incorporate high dose dexamethasone, well known to cause muscle atrophy, and patients may be on therapy for many years prior to becoming eligible for commercial products with associated detrimental effects from cumulative toxicities...Results The cohort consisted of 61 patients, 55 (90%) received ide-cel and 6 (10%) received cilta-cel...Although high prevalence of sarcopenia in this sample may preclude statistical detection of its adverse clinical impacts, it is clearly a significant clinical issue for patients undergoing complex immunotherapies for MM and warrants further research and intervention. Pre-habilitation strategies may be beneficial while patients are awaiting apheresis availability, or during cell manufacturing.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_2497;    
    A risk prediction model utilizing albumin, comorbidity burden, myosteatosis, and treatment intensity was able to reliably predict older adults at increased risk of severe toxicity. If independently validated in external datasets, our results can inform treatment selection for older adults with DLBCL undergoing first-line chemo-immunotherapy.
  • ||||||||||  Clinical, Journal:  Preoperative Considerations for the Frail Patient. (Pubmed Central) -  Nov 4, 2022   
    Identifying this cohort of patients before stressor events such as spinal surgery can prove paramount to improving the postoperative outcomes of these patients. This review provides a pertinent descriptive analysis to aid identification of frailty in a clinical setting, in addition to outlining methods of preoperative intervention that may improve postoperative outcomes.
  • ||||||||||  Preclinical, Journal:  An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. (Pubmed Central) -  Nov 4, 2022   
    Furthermore, metabolic changes of gastrocnemius after Semaglutide intervention were analyzed, and 141 kinds of differential metabolites were screened out, mainly embodied in lipids and organic acids, and enriched in 9 metabolic pathways including a variety of amino acids. Semaglutide can significantly reduce the body weight and the accumulation of intramuscular fat, promote muscle protein synthesis, increase the relative proportion of skeletal muscle, and improve muscle function of obese mice, possibly by altering the metabolism of muscle lipids and organic acids.
  • ||||||||||  Review, Journal:  Poor Oral Health and Sarcopenia in the Elderly:a Review of Their Correlation and Intervention Measures (Pubmed Central) -  Nov 4, 2022   
    Semaglutide can significantly reduce the body weight and the accumulation of intramuscular fat, promote muscle protein synthesis, increase the relative proportion of skeletal muscle, and improve muscle function of obese mice, possibly by altering the metabolism of muscle lipids and organic acids. Sarcopenia is a common geriatric syndrome associated with the occurrence of adverse consequences such as falls,debility,and death,seriously affectingthe quality of life of the elderly.Oral health as the basis of the overall health plays a vital role in improving the overall quality of life and extending the healthy life span of the elderly.Studies have demonstrated that poor oral health may increase the risk of sarcopenia.By reviewing the recent studies about oral health and sarcopenia in the elderly,we summarize the related mechanisms and put forward some intervention measures,so as to provide a theoretical basis for the prevention and treatment of sarcopenia from the aspect of oral health.
  • ||||||||||  Trial primary completion date:  The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. (clinicaltrials.gov) -  Nov 4, 2022   
    P=N/A,  N=17, Active, not recruiting, 
    Since RDI and PMI reduction rate can be predicted preoperatively, respectively, interventional consideration is possible for optimal adjuvant therapy in gastric cancer. Trial primary completion date: Mar 2023 --> Nov 2022
  • ||||||||||  Biomarker, Review, Journal:  Perspectives on Sarcopenia as a Predictor for Outcomes in Pediatric Patients with Chronic Liver Disease. (Pubmed Central) -  Nov 3, 2022   
    Finally, although various methods of muscle mass quantification are utilized, the most reported is the total psoas muscle surface area (tPMSA) on computed tomography. This method, along with others such as skeletal muscle area and skeletal muscle index, have had normative values recently defined and these collective efforts should enable researchers a common basis of comparison when delineating sarcopenia, and its impact, across various study populations in future investigations - including in children with liver disease.
  • ||||||||||  Review, Journal:  Assessment of body composition by whole-body densitometry: what radiologists should know. (Pubmed Central) -  Nov 3, 2022   
    Although a DEXA examination provides a lot of information, there is still no universal standardization of the parameters to be included in radiology reports. The aim of this study was to review the most relevant information for assessing body composition by whole-body densitometry.
  • ||||||||||  Preclinical, Journal:  Elamipretide effects on the skeletal muscle phosphoproteome in aged female mice. (Pubmed Central) -  Nov 3, 2022   
    This study tested whether 8-week treatment with elamipretide also affects global phosphorylation in skeletal muscle consistent with functional improvements and S-glutathionylation. Using female 6-7-month-old mice and 28-29-month-old mice, we found that phosphorylation changes did not relate to S-glutathionylation modifications, but that treatment with elamipretide did partially reverse age-related changes in protein phosphorylation in mouse skeletal muscle.
  • ||||||||||  Review, Journal:  Transcription factor NRF2 as potential therapeutic target for preventing muscle wasting in aging chronic kidney disease patients. (Pubmed Central) -  Nov 3, 2022   
    Whether deficiency of nuclear factor erythroid 2-related factor 2 (NRF2), which regulates expression of antioxidant proteins protecting against oxidative damage triggered by inflammation, may exacerbate PEW has yet to be examined in aging patients with CKD. This review focuses on the hypothesis that NRF2 is involved in the maintenance of muscle mass and explores whether sustained activation of NRF2 by non-pharmacological interventions using nutraceutical activators to improve redox homeostasis could be a plausible strategy to prevent skeletal muscle disorders, including muscle wasting, sarcopenia and frailty associated with PEW in aging CKD patients.
  • ||||||||||  Review, Journal:  Sarcopenia in Immune-Mediated Rheumatic Diseases-Review. (Pubmed Central) -  Nov 3, 2022   
    Furthermore, the impacts of sarcopenia are not well-appreciated, and the implementation of treatment strategies has not been widespread. Strategies such as exercise and some pharmacological treatments are effective in improving physical and functional impairment related to these conditions.
  • ||||||||||  Biomarker, Journal:  A pro-inflammatory diet increases the risk of sarcopenia components and inflammatory biomarkers in postmenopausal women. (Pubmed Central) -  Nov 3, 2022   
    Higher DII scores were significantly associated with decreased appendicular skeletal muscle (ASM) (β = -0.520), height-adjusted ASM (β = -0.116), weight-adjusted ASM (β = -0.469), knee extensor strength (β = -3.175), knee flexion strength (β = -1.941), increased body fat percentage (β = 1.238), and erythrocyte sedimentation rate (β = 5.582) (all P < .05). The present study confirmed a lower DII score, indicating that an anti-inflammatory diet is associated with higher muscle mass and strength and lower levels of inflammatory biomarkers.
  • ||||||||||  Journal:  Cardiac troponin T and autoimmunity in skeletal muscle aging. (Pubmed Central) -  Nov 2, 2022   
    Most importantly, anti-cTnT autoantibodies were detected in the blood of cTnT knockin mice, old mice, and older humans. Our findings suggest a novel cTnT-mediated autoimmune response may be an indicator of sarcopenia.